<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Robertson SJ</submitter><funding>Intramural NIH HHS</funding><funding>Division of Intramural Research, National Institute of Allergy and Infectious Diseases</funding><pagination>4481</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10368652</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Inflammation in response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection drives severity of coronavirus disease 2019 (COVID-19) and is influenced by host genetics. To understand mechanisms of inflammation, animal models that reflect genetic diversity and clinical outcomes observed in humans are needed. We report a mouse panel comprising the genetically diverse Collaborative Cross (CC) founder strains crossed to human ACE2 transgenic mice (K18-hACE2) that confers susceptibility to SARS-CoV-2. Infection of CC x K18-hACE2 resulted in a spectrum of survival, viral replication kinetics, and immune profiles. Importantly, in contrast to the K18-hACE2 model, early type I interferon (IFN-I) and regulated proinflammatory responses were required for control of SARS-CoV-2 rep</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Genetically diverse mouse models of SARS-CoV-2 infection reproduce clinical variation in type I interferon and cytokine responses in COVID-19.</pubmed_title><pmcid>PMC10368652</pmcid><funding_grant_id>1ZIAAI001125-04</funding_grant_id><funding_grant_id>ZIA AI001125</funding_grant_id><pubmed_authors>Shamsaddini A</pubmed_authors><pubmed_authors>Best SM</pubmed_authors><pubmed_authors>Bedard O</pubmed_authors><pubmed_authors>Gardina P</pubmed_authors><pubmed_authors>Harder JM</pubmed_authors><pubmed_authors>Robertson SJ</pubmed_authors><pubmed_authors>Bruno DP</pubmed_authors><pubmed_authors>Sturdevant GL</pubmed_authors><pubmed_authors>Holland SM</pubmed_authors><pubmed_authors>Leung JM</pubmed_authors><pubmed_authors>Sun J</pubmed_authors><pubmed_authors>Clancy CS</pubmed_authors><pubmed_authors>Shaia C</pubmed_authors><pubmed_authors>Chiramel AI</pubmed_authors><pubmed_authors>Brunton C</pubmed_authors><pubmed_authors>Munger S</pubmed_authors><pubmed_authors>Lewis M</pubmed_authors><pubmed_authors>Forte E</pubmed_authors><pubmed_authors>McNally KL</pubmed_authors><pubmed_authors>Broeckel RM</pubmed_authors><pubmed_authors>Preuss C</pubmed_authors><pubmed_authors>Shannon JG</pubmed_authors><pubmed_authors>Martens C</pubmed_authors><pubmed_authors>Baker CN</pubmed_authors><pubmed_authors>Rosenthal NA</pubmed_authors><pubmed_authors>Lack JB</pubmed_authors><pubmed_authors>Rosenke R</pubmed_authors><pubmed_authors>Anzick SL</pubmed_authors><pubmed_authors>Sturdevant DE</pubmed_authors></additional><is_claimable>false</is_claimable><name>Genetically diverse mouse models of SARS-CoV-2 infection reproduce clinical variation in type I interferon and cytokine responses in COVID-19.</name><description>Inflammation in response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection drives severity of coronavirus disease 2019 (COVID-19) and is influenced by host genetics. To understand mechanisms of inflammation, animal models that reflect genetic diversity and clinical outcomes observed in humans are needed. We report a mouse panel comprising the genetically diverse Collaborative Cross (CC) founder strains crossed to human ACE2 transgenic mice (K18-hACE2) that confers susceptibility to SARS-CoV-2. Infection of CC x K18-hACE2 resulted in a spectrum of survival, viral replication kinetics, and immune profiles. Importantly, in contrast to the K18-hACE2 model, early type I interferon (IFN-I) and regulated proinflammatory responses were required for control of SARS-CoV-2 rep</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2025-04-04T20:33:03.812Z</modification><creation>2025-02-19T00:26:33.272Z</creation></dates><accession>S-EPMC10368652</accession><cross_references><pubmed>37491352</pubmed><doi>10.1038/s41467-023-40076-5</doi></cross_references></HashMap>